Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor by unknown
LYSIS  OF  TUMOR  BIOPSY  CELLS  BY AUTOLOGOUS 
T  LYMPHOCYTES  ACTIVATED  IN MIXED  CULTURES  AND 
PROPAGATED  WITH  T  CELL  GROWTH  FACTOR* 
BY FARKAS VANKY, TIKVA GORSKY, YORAM GORSKY, 
MARIA-GRAZIA MASUCCI, AND EVA KLEIN 
From the Department of Tumor Biology, Karolinska Institute and the Radiumhemmet, Karolinska Hospital, 
S- 104 Ol Stockholm 60, Sweden 
A proportion of patients with carcinomas and sarcomas possess blood lymphocytes 
that  can  lyse  their  freshly  harvested  tumor  cells  in  vitro  (I-4).  To  enhance  such 
cytotoxicity, we activated the lymphocytes either in mixed cultures with autologous 
tumor biopsy cells (ATS) 1 or in conventional mixed lymphocyte cultures  (MLC). In 
accordance with the results of Zarling et al.  (5),  with leukemia cells, MLC-activated 
lymphocytes were  often  cytotoxic  for  autologous  and  third-party  allogeneic  solid 
tumor cells (6). Cocultivation with the patients' tumors generated autotumor cytotox- 
icity in the majority of experiments (7-9). In contrast to the MLC, these lymphocytes 
did not lyse allogeneic tumor biopsy cells. 
The  effects  against  autologous  and  third-party  tumors  by  the  patients'  MLC- 
lymphocytes might be a consequence of activation of lymphocyte sets that recognize 
(a) antigens that cross-react with the stimulator lymphocytes (b) tumor-related anti- 
gens shared by tumor cells of the lymphocyte donor and the allogeneic tumor, and 
(c)  distinct  allo- and/or tumor-related antigens on the different  targets.  Cold target 
competition experiments presented in this paper suggest that the third alternative is 
valid. 
Establishment of growing T  cell lines with maintained specific functions  (cytotox- 
icity or proliferative capacity)  is an important step in the progress of tumor immu- 
nology (10-17).  Such T  cell populations reacting with autologous tumor cells might 
help in the study of the cell surface antigens of tumor cells, and they may be exploited 
in therapeutical measures. 
Because T  cell growth factor (TCGF)  (interleukin 2;  IL-2) promotes the growth of 
activated T  cells  (18),  its use imposes a  selection  for propagation of specific clones 
when  applied  to  populations  preexposed  to  the  relevant  antigen.  To  raise  specific 
autotumor killer T  cell cultures from patients with solid tumors, we cultured the blood 
lymphocytes first  with  the  autologous  tumor cells  and  thereafter  added  TCGF  to 
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expand  the  responding  population.  We  compared  these  and  the  MLC-activated, 
TCGF-propagated lymphocytes from the same patient with regard to cytotoxicity for 
autologous and allogeneic tumor biopsy cells. The results showed that the reactivity 
of the growing T  cell cultures reflects the characteristics of the population from which 
they were initiated. 
Materials and  Methods 
Tumor Cells.  These cells were  separated from  surgical specimens of seven  patients with 
malignancies of various histologic types (tumor 898  is B  cell lymphoma;  tumors  1,044  and 
1,045 are osteosarcomas; tumors 2,207  and 2,285  are oat cell carcinomas of the lung; tumor 
2,286  is a  squamous  cell carcinoma on  the  lung;  and  tumor  513  is a  hypernephroma)  by 
stepwise application of velocity and  density sedimentations of Ficoll-Isopaque (FI) and  on 
human serum albumin gradients, treatment with collagenase and deoxyribonuclease (DNase), 
as well as adherence  to  a  plastic surface  (2,  19). The  isolated tumor  cells were  incubated 
overnight in culture conditions before their use, to allow resynthesis of cell surface antigens 
assumed to be affected in vivo and/or during the procedure of cell separation. Experiments 
were performed only with cell suspensions that  had at least 80% cell viability as assessed by 
trypan blue exclusion and that had <5% obvious contamination with nonmalignant cells. 
Samples of tumor cells (2 ×  106 to 5 ×  106 vials) were stored in liquid nitrogen as previously 
described (2) to use as targets for the cultured effectors. The thawed cells were diluted gradually 
to 10 ml medium plus 20% normal human serum. When necessary, dead cells were removed by 
centrifugation on FI. 
Cell Lines.  The erythroid line K-562 (20) and the Burkitt's lymphoma line Daudi (21) were 
maintained in suspension cultures in RPMI  1640  medium supplemented with  10% fetal calf 
serum. 
Lymphocytes.  Lymphocytes from patients and healthy donors were separated from heparin- 
ized blood on FI, followed by incubation in plastic culture flasks (type 3023;  Falcon Labware, 
Div. of Becton, Dickinson & Co., Oxnard, Calif.) for 30 min at 37°C to remove adherent cells. 
One aliquot of the total nonadherent population was treated with mitomycin-C and used as 
stimulator in the MLC. For effectors in the direct cytotoxicity tests and for responders in the 
various types of mixed cultures, the lymphocytes were passed through a  nylon fiber column 
(22).  The  nylon column-passed (NCp)  lymphocyte population contained mainly T  cells; in 
indirect immunofluorescence, 97-100% reacted with the monoclonal antibody OKT3, specific 
for circulating T  cells (23),  and 0-2% reacted with the OKIal antibody, reacting with the Ia 
antigen (24,  25).  The monoclonal antibodies were obtained from G. Goldstein (Ortho Phar- 
maceutical Co., Raritan, N. J.). 
Tissue  Culture Medium.  RPMI  1640  medium  (Flow  Laboratories  Ltd.,  Irvine,  Ayrshire, 
Scotland) with L-glutamine (200-mM solution, 1% by volume), benzyl-penicillin (100 IU/ml), 
streptomycin sulphate (100/zg/ml),  Hepes buffer (20  mM),  and  10% concentration of heat- 
inactivated serum  (from healthy male donors) was used in all experiments. The human sera 
were not preselected, but cloudy preparations were excluded. 
Stimulation with  PHA.  NCp  lymphocytes (10  7 cells/10 ml)  were cultured with 0.5 ~g/ml 
purified phytohemagglutinin (PHA; Wellcome Reagents Ltd., Beckenham, England)  for 3-4 
d. These cells, 60-70% T  blasts, were used either as effectors or as targets. When used in the 
cold target competition assays, they were exposed to chilled formaldehyde (0.4% solution in 
phosphate-buffered saline, pH 7.2) and kept in an ice bath for 30 min. Thereafter, they were 
washed with phosphate-buffered saline three times, the first wash being at 0°C (26). 
Mixed Lymphocyte Cultures.  Aliquots of the NCp lymphocytes (10  ×  106 to  15  ×  106 cells/ 
flasks) were mixed either with 0.5 ×  106 to 1.5 ×  106 autologous tumor biopsy cells for the ATS 
(we found the optimum ratios within this range), or with 5 X  106 to  7 X  106 mitomycin C- 
treated  allogeneic lymphocytes (total population and/or the  nylon column-attached  INCa] 
fraction) for the MLC. The  10- to  15-ml cultures were incubated for 5-6 d  in plastic culture 
flasks (type 1013; Falcon Labware) at 37°C in a  5% CO2-containing humidified atmosphere. 
On day 5, one-half of the medium was replaced. V,~,NKY ET AL.  85 
The 6-d MLC and  ATS cultures  contained  95-100%  OKT3,  23-30%  OKIal, and  0-2% 
OKM 1-reacting cells. The emergence of OKIal reactivity is a sign of T cell activation (25). 
Propagation of the T Cell Cultures.  MLC and PHA-stimulated aliquots of lymphocytes were 
exposed to TCGF on day 6, and the ATS cultures were exposed on day 10. They were further 
propagated in culture medium containing 50% TCGF for 2-4 wk. 
The source of TCGF was the supernatant of cultured FI-separated lymphocytes of healthy 
blood donors. The lymphocytes were incubated with Welleome PHA-P (100/~g/108 cells per ml 
for 30 min at 37°C, followed by six washes and thereafter incubated  (106 cells/ml)  in serum- 
free RPMI  1640 tissue  culture medium for 48 h. The duplication time of the TCGF cultures 
was 2.5 d. 
All cells from these cultures reacted with OKT3, and 30% also reacted with OKIal antibody. 
No OKMl-reactive cells were detected. 
Cytotoxic Assay.  A  modification of the method described by Vose et al.  (1)  has been used 
(19). The percentage of 51Cr release  was calculated  from the  following formula:  (counts in 
supernatant per counts in supernatant and pellet ×  100). The percent specific 5~Cr release was 
then determined by the following formula: 
(percent release  in test -- percent spontaneous release) 
×  100 
(percent maximum release  -  percent spontaneous release) 
Tests in which the spontaneous release  exceeded 50% were disregarded.  Statistical  signifi- 
canoes were calculated on the cpm values of the triplicate samples by the Student's l test. 
Cold Target Competition.  The effectors (5 X  l0  s cell/well)  were dispersed  in 50 #1 medium, 
and various numbers of unlabeled targets were added in 50/~1. The ratios of effector to cold 
targets  were  100:1,  50:1, and  25:1. The plates were then  centrifuged at  800 g  for  10 s and 
incubated for 30 rain at 37°G. They were then shaken (Titretek plate shaker, Flow Laboratories 
Ltd, Irvine, Ayrshire, Scotland) and the SXGr-labeled targets (104 cells/wel D were added in 100 
/11 medium. (The ratios of labeled:unlabeled cells varied between 5:1 and  1:5). The volume in 
each well was adjusted to 200 ~1. After centrifugation (800 g for 10 s), the plates were incubated 
and  processed as the usual  cytotoxic assays.  Statistical  significances were calculated  on the 
triplicates of cpm values by the Student's t test. 
Results 
Cytotoxicity of MCL-activated Lymphocytes of Healthy Donors.  Lymphocytes cultured in 
conventional  MLC were cytotoxic against  blasts of the stimulator.  In addition,  they 
lysed the K-562 and Daudi cells in all cases; they lysed third  party allogeneic  PHA 
blasts,  TCGF blasts,  and tumor biopsy cells  in 3/4,  3/4,  and 5/8  tests,  respectively. 
Autologous TCGF or PHA blasts were not damaged  (Table I). 
Cytotoxicity of A TS or MLC-activated  Lymphocytes of Tumor Patients.  Aliquots  of the 
patients'  lymphocytes were activated  in ATS and  MLC  (Tables  II and  III). Before 
activation,  two  patients  (513  and  2,285)  exhibited  cytotoxicity  against  their  own 
tumor cells  (20 and  34% specific release,  respectively).  In all  experiments,  the lym- 
phocytes cultured with autologous tumor biopsy cells lysed these cells when tested on 
day 6. Allogeneic tumor cells and autologous or allogeneic PHA blasts were not lysed. 
Thus, the cytotoxicity was specific for the stimulator cells. 
In  contrast,  the  lymphocytes  of  the  MLC  were  cytotoxic  for  the  autologous, 
allogeneic third-party  tumor biopsy cells and  for allogeneic PHA blasts  in 3/5,  5/7, 
and 4/4 of tests, respectively. Autologous PHA blasts were not lysed (four tests). These 
results thus confirmed that lymphocytes activated in MLC can lyse autologous tumor 
ceils  (5,  6)  and  we  now  show  that  they  do  not  lyse  autologous  PHA  blasts.  In 
accordance with our previous results, the generation of autotumor killer cells occurred 
more regularly in the autologous mixed cultures than  in MLC, and the cytotoxicity 
was specific for the autologous tumors. 86  AUTOLOGOUS  TUMOR  KILLER  T  CELL  CULTURES 
TASLE  I 
Cytotoxicity of MLC-activated Lymphocytes  from Healthy Donors Tested Directly or after Propagation with 
TCGF* 
Target  cells 
Experi-  Propaga-  PHA  blasts  TCGF  blasts  Tumor  Cell lines 
ment  tion with  biopsy 
numbers  TCGF 
Autolo-  Alloge-  Autoto-  Alloge-  Allogeneic§  K-562  Daudi 
gous  neic~:  gous  neic~: 
1  -  0  2311  --  -- 
2  -  o  1811  -  - 
3  -  0  2711  --  -- 
4  -  0  10  --  -- 
5  --  --  --  0  14 
+  --  --  0  64 
6  -  --  --  0  20 
+  --  --  0  54 
7  -  --  --  0  15 
+  --  --  0  60 
8  -  --  --  0  0 
+  --  --  0  35 
2511  34[1  - 
3oll  o  - 
3311  o  - 
2o11  13  -- 
--  --  57 
--  --  67 
--  --  60 
--  --  60 
--  --  41 
--  --  46 
--  --  50 
--  --  59 
n 
m 
4911 
5911 
* Lymphoeytes  were cultured  with allogeneic lymphocytes  for 6  d.  Aliquots were removed  for cytotoxicity 
assays and thereafter the cultures were further propagated  with TCGF  for 2 wk. The  values represent  the 
percentage-specific SlCr release in a  4-h assay at an effector:target  ratio of 50:1. 
:~ In  experiments  2  and  4,  the  PHA  blasts  were  derived  from  third-party  donors,  otherwise  the  PHA  or 
TCGF  blasts are identical  to the stimulators. 
§  Each test was performed  with a  different  tumor. 
11 Statistical  significance, P  <  0.05. 
TABLE  II 
Cytotoxicity of Patients' Lymphocytes Activated in A TS or MLC* 
Lympho- 
cyte donor 
Lymphocytes  cultured  in ATS  Lymphocytes  cultured  in MLC:~ 
Autologous  Allogeneic  Autologous  Allogeneic 
targets  targets  targets  targets 
Tumor  Tumor 
PHA  PHA  PHA  PHA 
Tumor  blasts  A  B  blasts  Tumor  blasts  A  B  blasts§ 
2,285  21  2  4  --  --  7  0  20[[  24U  -- 
t,044  33  0  5  --  0  20[[  2  25[f  --  50t{ 
1,045  26  0  0  2  0  291I  5  I2  --  38[[ 
513  22  --  5  0  0  0  --  65]]  --  45 H 27 
2,286  30  --  11  9  2  321[  --  2511  11  -- 
* Aliquots  of lymphocytes  were cultured  with  autologous  tumor  cells  or allogeneic  lymphocytes  for  6  d. 
The  values represent the percentage specific ~Cr  release in a  4-h assay at an effector:target  ratio of 50:1. 
:~ Lymphocytes  of healthy donors were the stimulators  in the MLC. 
§ Allogeneic PHA  blasts were derived from the stimulators. 
I] Statistical  significance, P  <  0.01. 
Characterization of the Cytotoxicity  Generated in A TS and MLC.  Cold target competition 
tests were performed  in systems in which ATS  (Fig.  1 A) and  MLC  (Fig.  1 B  and  C) 
activated  the lymphocytes  of a  lung carcinoma  patient  (2,286),  and  the  targets were 
either  autologous  (Fig.  1 A  and  B)  or  allogeneic  (2,285)  tumor  (Fig.  1 C).  The V~i,  NKY  ET  AL.  87 
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Fro. I.  Cold target  competition tests  with ATS and MLC-activated lymphocytes from patient 
2,286. Tumor cells from two biopsies, the autologous squamous cell carcinoma of the lung (panels 
A and B) and the altogeneic oat cell carcinoma of the lung 2,285 (panel C), were used as labeled 
targets. The patient's [ymphocytes, activated by exposure to autologous tumor biopsy cells (panel 
A) and by allogeneic lymphocytes of an unrelated healthy donor,  I, (panel  B and C), were the 
effectors. -  .... designates that the labeled and unlabeled targets are identical; X indicates the level 
of cytotoxicity in absence of cold targets. Cold targets: autologous tumor 2,286 (Q), allogenelc tumor 
2,285 (m), and the PHA blasts of the stimulator (A) of tumor patients 2,286 (Q)) and 2,285 (Q). The 
effector:labeled target ratio was 50:1. Cytotoxicity, 4 h 51Cr release assay. 
autotumor  killing was  inhibited exclusively by the  identical cold tumor  cells inde- 
pendent of whether this was generated in ATS or MLC. It is important to note that 
autologous PHA blasts did not compete. The lysis of the third party allogeneic tumor 
by the MLC-activated effectors was inhibited both by these tumor cells and by PHA 
blasts  from  the same  individual.  In  this  combination,  autologous tumor  and  PHA 
blasts  did  not  compete  (Fig.  1 C).  PHA  blasts  of the  stimulator  did  not  compete 
either. 
These results show (a) the tumor "specificity" of the killer subset, which acts on the 
autologous tumor  cells, independent  of whether  it was  generated  in  ATS  or  MLC 
because autologous PHA blasts did not  inhibit; and  (b)  that  neither the autologous 
nor  the third party allogeneic tumor  killing of MLC  cells is due  to cross-reactivity 
with the stimulator lymphocytes. 
Fig.  2  presents  a  criss-cross  cold  target  competition  test  with  MLC-activated 
lymphocytes from  two  patients  (hypernephroma  513  and osteosarcoma  1,044).  The 
stimulator lymphocytes were derived from an unrelated healthy donor (Fig. 2 A  and 
B).  The  cytotoxicities in  the  allogeneic criss-cross tests  were  inhibited  by  the  cold 
tumor cells identical with  the labeled ones  and  also by PHA  blasts from  the same 
patient but not by the tumor cells or PHA blasts of the responder (Fig. 2 A  and B). 
The MLC-activated lymphocytes of patient  1,044 were also cytotoxic for autologous 
tumor cells (Table III), but  these did not  compete  in  the assay with  the allogeneic 
tumor 513  (Fig. 2 B). 88  AUTOLOGOUS TUMOR  KILLER T  CELL CULTURES 
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Fic.  2.  Cold target competition  tests in the MLC-activated  cytotoxic system. Tumor cells from 
three biopsies, osteosarcoma 1,044 (panel A), hypernephroma 513 (panel B), and osteosarcoma 1,045 
(panel C)  were used as labeled targets. MLC-activated  lymphocytes from patient 513  were the 
effectors against 1,044 tumor cells (panel A), and lymphocytes 1,044 were the effectors against tumor 
513  (panel  B), thus  representing a criss-cross test in allogeneic conditions. The healthy donor's 
lymphocytes activated by the lymphocytes of patient  1,045 were the effectors in panel  C. Cold 
targets: tumor biopsy cells 1,044 (11), 513  (O), and  1,045 (O); formaldehyde-treated  PHA blasts 
from patients  1,044 Or), 513 (4), 1,045 (/X), and from the healthy donor that was the responder in 
panel C (El). For details see Fig. 1. 
The  cytotoxicity against  osteosarcoma  ceils  1,045,  exerted  by  lymphocytes  of a 
healthy donor activated by lymphocytes of patient  1,045, was inhibited only by the 
cells, both  tumor and  PHA blasts, derived from  the same patient. PHA blasts from 
the responder and tumor cells from another individual did not compete (Fig. 2 C). 
Because  in  these  experiments  the  same cells participated in  more  than  one  lytic 
system as competitors and the effect depended on their relation to the effector-target 
combination,  the  tests  are  inherently  controlled.  Thus,  it  seems  that  the  lysis  of 
allogeneic tumor cells by MLC-activated lymphocyte populations of tumor patients 
does not  occur on  the basis of recognition of cross-reacting tumor-related antigens. 
The competition by PHA blasts of the tumor cell donor indicate that the cytotoxicity 
of MLC  lymphocytes  for  third-party allogeneic tumor  cells occurs  on  the  basis of 
alloantigen recognition. In addition to the experiments presented  here,  results with 
four further tests involving nine patients led to the same conclusions. The killer cells 
are probably transactivated as a  corollary of the specific events in the culture. 
Cytotoxicity of the Activated Lymphocytes after Propagation in TCGF.  10-d-old lymphocyte 
cultures mixed with autologous tumor biopsy cells were further propagated in TCGF- 
containing medium. Two cultures (1,045 and 513) were available and could be tested 
for  cytotoxicity 4  wk  later.  These  cells lysed autologous  but  not  allogeneic tumor 
biopsy  ceils  (Table  III).  Because  the  experiment  involved  a  criss-cross  test,  the 
specificity was real and did not depend on the sensitivity of the targets. 
In contrast  to the preferential autotumor  killing of the ATS-TCGF  effectors, the 
TCGF cultures of the same lymphocytes preactivated in MLC were cytotoxic for both 
autologous and allogeneic tumor cells. K-562 cells were regularly damaged by these 
effectors, V,~,NKY  ET  AL.  89 
TABLE  III 
Cytotoxidty  of  Lymphocytes  Activated  in  A  TS,  MLC,  or  by  PHA  Tested  Directly  and  after  Propagation 
with  TCGF* 
Targets 
Lymphocyte  Type of  Propagated 
donor  culture  with TCGF  Tumor  biopsy cells:]: 
numbers 
PHA 
blasts 
2285  1044  1045  513  2207  898 
K-562 
2285  --  -  34  --  --  --  8  --  --  34 
MLC  -  7  --  --  --  20  --  24  32 
MLC  +  47  18  29  ....  33 
ATS  -  21  --  --  --  4  --  2  -- 
1044  --  -  --  0  --  0  .... 
MLC  -  --  20  --  25  --  --  50  43 
MLC  +  38  20  25  ....  38 
ATS  -  --  33  --  5  --  0  --  -- 
1045  --  -  --  0  6  2  .... 
MLC  -  --  --  29  12  --  --  38  25 
MLC  +  24  --  24  13  --  --  --  45 
ATS  -  2  --  26  0  --  --  --  25 
ATS  +  9  --  52  2  --  --  --  14 
513  --  -  --  9  --  20  --  --  --  28 
MLC  -  --  65  --  0  --  --  45  48 
MLC  +  39  --  30  24  --  --  --  41 
ATS  -  --  5  --  25  --  0  --  20 
ATS  +  0  --  9  29  --  --  --  14 
Healthy A  --  -  11  ....  0  --  0 
MLC  +  59  ....  21  --  62 
PHA  +  62  ....  19  --  64 
Healthy  B  --  -  7  ....  0  --  0 
MLC  +  38  ....  6  --  20 
PHA  +  51  ....  17  --  47 
* Aliquots of lymphocytes were  cultured in ATS,  MLC,  and  with PHA  (0.5 ~g/ml).  Cytotoxicity against 
frozen preserved tumor cells or fresh PHA  blasts was determined on day 6  in a  4-h 51Cr release assay. The 
cultures were further propagated  with TCGF.  Cytotoxieity of the MLC-TCGF  cultures was determined 
after  14  days,  and  the  ATS-TCGF  was  determined  4  wk  later.  The  values  represent  the  percentage 
specific 51Cr release. 
Tumors  1,044 and  1,045 are osteosarcomas,  tumors 2,207 and  2,285  are oat cell carcinomas of the lung, 
tumor  898 is a  B  cell lymphoma,  tumor  2,286 is a  squamous  cell carcinoma  of the lung, and  tumor  513 
is hypernephroma. 
The tumor biopsy cells were lysed by the healthy donors' lymphocytes propagated 
in TCGF after activation in MLC or PHA in  3/4  and in  1/4 of the experiments, 
respectively  (Table III). 
Discussion 
The goal of human tumor immunology studies is the demonstration of recognition 
of autologous  tumor  cells.  Even  if its  existence  does  not  ensure  that  the  immune 
mechanisms can  control  tumor  growth,  increasing  knowledge  of the  details  in  the 
immune  events  might  lead  to  its  therapeutical  exploitation.  There  is  considerable 
interest  in the establishment of tumor-reactive T  cell cultures. They would provide a 
tool for characterization of tumor-related antigens and might also contribute to the 
design of therapeutical strategies. 90  AUTOLOGOUS TUMOR  KILLER T  CELL CULTURES 
In previous experiments (6-9)  performed in our laboratory, patients' lymphocytes 
cultured with their own tumor cells killed these (in 67% of 77 cases) but not allogeneic 
tumor  cells.  MLC-activated  lymphocytes also  killed  the  autologous  tumor  biopsy 
cells, however, less frequently (3/19, 37%) and with lower efficiency (6). These effectors 
damaged more often the third-party allogeneic tumor cells (11/13,  85%). The exper- 
iments presented  in  this paper are in  accordance with our previous results.  Similar 
findings were reported  recently by Strausser  et  al.  (27).  In  7/10  experiments with 
MLC-activated  lymphocytes  (by single  donor  stimulator cells),  lysis of autologous 
solid tumor cells were obtained. Their effects were also rather weak (the highest 22% 
at  effector:target  ratio  25:1),  but  it  could  be  elevated  if "pool  stimulation"  was 
performed. 
The cold target competition experiments were performed with the aim of charac- 
terizing  the  cytotoxicities  directed  against  autologous  or  allogeneic  tumor  biopsy 
targets. Lysis of different targets by the same activated population can be performed 
by the same, by different, and by partially overlapping subsets. The experiments were 
designed  to  elucidate  whether  (a)  the  autotumor  killer  lymphocytes  generated  in 
MLC  are  members of the  same subset  that  recognize  the  stimulator  cells  and  (b) 
whether  the  allotumor  killer  subset  of the  patients  acts  via  recognition  of shared 
antigen(s) with the autologous tumor. 
The inhibition  of the autologous tumor killing by the identical  and not by other 
unlabeled  cells  suggests  that  the  effector lymphocytes recognize  tumor-  or  organ- 
specific antigens.  The fact that  the antitumor cytotoxicity of the  MLC population 
was not inhibited by the stimulator lymphocytes points also to the specificity of the 
lysis. This rules out the possibility that the tumor biopsy cells are attacked indiscrim- 
inately by the activated lymphocytes as is the case with the K-562 or Daudi cells (6, 
28). 
On the basis of our previous studies, we consider the lysis of K-562 cells to be a sign 
of the activated state of the lymphocytes. The mechanisms of this activity are different 
than the lysis of freshly harvested tumor cells. It seems that the effect against the cell 
lines is independent of antigen recognition, and it is due to some as yet undetermined 
properties  of their  plasma  membrane  (28,  29).  This  view  is  substantiated  by  the 
general competing potential of the K-562 cells in cytotoxic assays (30). 2 Consequently, 
in  the judgment  of the  specificity  of a  certain  reactivity  exerted  by  lymphocyte 
populations,  we do  not  take  into  account  the  anti-K-562  or anti-Daudi  effects but 
only the results against targets of similar type. 
Competition  with  the  PHA  blasts  of the  tumor  cell  donor  in  the  system  with 
allogeneic tumor target suggests that the cytotoxicity occurs on the basis of alloantigen 
recognition even when the MLC-activated effectors are derived from tumor patients. 
These  arguments  are  valid  provided  the  cold  target  competition  assays  can  be 
interpreted  to decide between distinct  and overlapping populations.  The method  is 
widely used, and up to the present there is no indication against this assumption. 
Similar  selective  cytotoxicities  were  revealed  in  our  previous  experiments  with 
interferon  (IFN)-activated fresh lymphocytes. Cold  target  competition tests showed 
that different allogeneic tumor targets are lysed by distinct subsets of the same effector 
population. Effects against an allogeneic tumor were inhibited only by identical cells 
2  V~.nky, F., and E. Klein. Alloreactive  cytotoxicity  of interferon-triggered  human lymphocytes  detected 
with tumor biopsy targets. Immunogenetics. In press. V,~NKY ET AL,  91 
or by PHA blasts from the same individual but not by other tumors or PHA blasts, 
although they were also lysed by the same effector population. 2 We interpreted the 
results as a polyclonal activation induced by short-term IFN treatment. In addition 
to the generation of specific CML, similar events occurred in the MLC cultures. 
In view of the high frequency of alloreactive cells in the lymphocyte population, 
clonai expansion might not always be necessary, but activation suffices to generate 
allospecific cytotoxicity. It is likely that in the MLC, production of IL-1 and IL-2 as 
a  corollary of antigen recognition even leads to activation and proliferation of cells 
that do not bear receptors for the stimulating antigen (31, 32). 
Characterization  of cytotoxic clones  in  primary  murine  MLC  populations  also 
showed distinct effector subsets against different targets. This approach revealed (33) 
that  in  addition  to the enlargement of the specific clone (representing 81% of the 
clones), cytotoxic cells reacting with third-party targets proliferated simultaneously 
(11% of the clones). 
The  lack  of alloactivation  in  the  ATS  is  probably  due  to  the  relatively  low 
proportion of autoreactive cells.  In a mouse system, comparison between the interac- 
tion of cytotoxic lymphocytes with syngeneic and allogeneic tumors showed that  in 
the syngeneic combination the frequency of the conjugate-forming lymphocytes and 
their  binding  avidity  was  lower  compared  with  the  allogeneic  one  (34).  Such  a 
difference is  reflected in  the  lower blastogeneic  response  in  cultures  of autologous 
lymphocytes and  tumor cells  (ATS)  compared with  MLC  (35).  The proportion of 
antigen-reactive cells may determine the  quantity of amplifying factors produced. 
The comparison of the generation of autotumor killing effectors by single or "pool" 
MLC stimulation indicates that this is the case (27). 
In  mice,  the  production  of soluble  mediators  differed when  K/D  and  I-region 
stimulation were compared with regard to the requirement of the Ly phenotype of 
the helper ceils  (31).  Therefore, the  different nature  of the  antigens  recognized in 
ATS and MLC may also be held responsible for the differences in the cytotoxic target 
spectrum generated. 
The  experiments  with  MLC  lymphocytes  show  that  cells  that  react  with  the 
autologous  tumor  can  be  activated  by  nonspecific  means.  The  results  with  solid 
tumors  were  thus  similar  to  those  obtained  with  leukemias.  Cytotoxicity against 
autologous leukemia cells were generated in mixed cultures by confrontation with a 
pool  of allogeneic  lymphocytes or  leukemia  blasts  and  BCG  extract  (5,  36).  Our 
experiments indicate that the ATS cultures provide the best system for generation of 
autotumor cytotoxicity. 
In  our  previous  experiments,  fresh  lymphocytes were  activated  by  IFN  to  kill 
allogeneic but  not  autologous  tumor  cells.  The  observation  with  the  ATS  system 
concerning the high proportion of cases (67%)  with autotumor-recognizing lympho- 
cytes conflicts with the lack of IFN-activated killing against autologous tumors. The 
obvious cause may be the absence or low number of tumor-recognizing lymphocytes 
in a state of differentiation that can be enhanced for lytic functions by IFN. We have 
shown  (37)  that  IFN does not act on separated  Fcy receptor-negative T  cells.  This 
subset represents a high proportion of the blood lymphocyte population and contains 
the iymphocytes that are triggered for multiplication by confrontation with antigens 
(38). 
The selective cytotoxicity  for the autologous tumor ceils of the ATS cultures and 92  AUTOLOGOUS TUMOR  KILLER  T  CELL  CULTURES 
the wider reactivity of the MLC was maintained in the growing cultures.  Because of 
the exclusive reactivity of activated T  cells with  the growth-promoting factor IL-2, 
the  initial  events  in  the  cultures  determine  thus  the  characteristics  of the  TCGF 
cultures  (18). 
In experiments with auto- and allogeneic lymphoblastoid lines  (LCL), Sumiya et 
al.  (39)  have showed  that  in  primary mixed cultures  cytotoxicity was  generated  in 
autologous cultures with specificity for the auto-LCL. After reciprocal restimulation, 
the secondary cytotoxicity reflected the characteristics of the primary cultures,  i.e., 
auto-LCL specificity was maintained  after the  secondary exposure to allo-LCL.  In 
this system, cocultivation with allo-LCL also generated some auto-LCL lysis, although 
this was weak. 
The early commitment  determining  specific reactivity has been  directly  demon- 
strated with T  cell colonies raised after brief exposure to allogeneic lymphocytes and 
grown with TCGF (16). 
It remains to be seen whether the distinctness of the cytotoxic lymphocyte subsets 
for different  targets,  as it was seen  in  MLC,  is maintained when  these cultures  are 
further propagated. 
In vivo events that parallel the autotumor reactivity of the MLC population have 
been  described  in  the  experimental  system.  Allosensitivation  was  shown  to  confer 
protection  of mice and  rats  against  the  outgrowth  of syngeneic tumor  grafts  (41). 
Nonspecific immunostimulation has been attempted in the therapy of human tumors. 
On the basis of the results in experimental models and in vitro assays, more substantial 
success would  have been expected.  However, the  possible reasons  for the  failure of 
such measures are numerous. 
The generation of autotumor-reactive T  lymphocyte cultures by a single exposure 
of the  lymphocytes to  the  autologous  tumor  cells  is  important  in  the  view of the 
limitation  in  the  amount  of tumor tissue  that  can  be collected  from the  patients. 
Because "transactivation" in the MLC may also induce the autotumor-reactive cells 
to exert cytotoxicity, "nonspecific" measures can be exploited in the absence of or in 
extreme scarcity of available tumor tissue. 
Summary 
Blood lymphocytes from tumor patients were cocultivated with allogeneic lympho- 
cytes (MLC) or autologous tumor cells (ATS), and their cytotoxicity was character- 
ized. The main objective of the study was the lysis of autologous tumor biopsy cells by 
such effectors. Lymphocytes of patients activated in MLC lysed allogeneic third-party 
cells and in some cases also lysed autologous tumor cells. Allogeneic but not autologous 
PHA blasts were also damaged by these effectors. The cytotoxic potential of MLC- 
activated  lymphocytes  from  healthy  donors  was  similar;  allogeneic  tumors  and 
phytohemagglutinin  (PHA) blasts but not autologous PHA blasts were lysed. 
The cytotoxicity of lymphoeytes activated in ATS were specific for the stimulator 
because  they  acted  only  on  the  autologous  tumor  cells.  Allogeneic  tumors  and 
autologous  and  allogeneic  PHA  blasts  were  not  lysed.  The  pattern  of cytotoxicity 
with regard to this target panel was maintained when the MLC or ATS cultures were 
further propagated with TCGF. 
Results obtained in cold target competition assays suggested (a) activated lympho- 
cyte lyse the third party tumor targets because of alloantigen recognition; (b) in MLC V,,i, NKY ET AL.  93 
several different sets of alloreactive cytotoxic lymphocytes are present simultaneously; 
and (c) the alloreactive cells are different than those that act on the autologous tumor 
cells. Thus, the lysis of allogeneic tumor cells by lymphocytes of the patient is not due 
to recognition of cross-reacting tumor-related antigens, and the autotumor cytotoxieity 
of the  patients'  MLC-activated  lymphocytes  is  performed  by  specifically  reacting 
cells. 
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